Active substancePotassium and magnesium asparaginatePotassium and magnesium asparaginate
Similar drugsTo uncover
  • Aspark
    pills inwards 
    MARBIOFARM, OJSC     Russia
  • Aspark
    pills inwards 
    RED STAR HFZ, OJSC     Ukraine
  • Aspark
    pills inwards 
    GALICHFARM, PAO     Ukraine
  • Aspark
    pills inwards 
  • Aspark
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Aspark
    pills inwards 
    MEDISORB, CJSC     Russia
  • Aspark
    pills inwards 
  • Aspark
    pills inwards 
    LUHANSKY HFZ, OJSC     Ukraine
  • Aspark
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Aspark
    pills inwards 
    FARMAPOL-VOLGA, LLC     Russia
  • Aspark
    pills inwards 
  • Aspark
    pills inwards 
    YUZHFARM, LLC     Russia
  • Aspark
    pills inwards 
    ATOLL, LLC     Russia
  • ASPEKARA AVEKSIMA
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Asparkam-L
    solution in / in 
    BIOSINTEZ, PAO     Russia
  • Asparks-UBF
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Asparks-Farmak
    solution in / in 
    FARMAK, PAO     Ukraine
  • Potassium and magnesium asparaginate
    solution d / infusion 
  • Potassium and magnesium asparaginate
    concentrate d / infusion 
  • BERLIN-PHARMA, CJSC     Russia
  • Panangin
    solution d / infusion 
    GEDEON RICHTER, OJSC     Hungary
  • Panangin®
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Panangin® Forte
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Dosage form: & nbsppills
    Composition:

    Composition per one tablet.

    Asparcum - 500 mg

    [magnesium aspartate tetrahydrate 177 mg

    potassium asparaginate hemihydrate - 177 mg

    Excipients:

    potato starch - 131 mg

    talc - 10 mg

    calcium stearate] - 5 mg

    Description:Round flat cylindrical tablets of white color, with a facet, with a risk on one side and engraved "R" or without it - on the other.
    Pharmacotherapeutic group:Potassium and magnesium preparation
    ATX: & nbsp

    A.12.C.X   Preparations of other minerals

    Pharmacodynamics:

    Aspartame is a source of potassium and magnesium ions, regulates metabolic processes, helps restore electrolyte balance, and has antiarrhythmic effect.

    The potassium ion participates both in carrying out impulses along nerve fibers, and in synaptic transmission, the implementation of muscle contractions, and the maintenance of normal cardiac activity. Disturbance of potassium ion exchange leads to a change in the excitability of nerves and muscles.Active ionic transport maintains a high gradient of potassium ions through the plasma membrane. In small doses, the potassium ion dilates the coronary arteries and, in large doses, narrows. Has a negative chrono- and batmotropic effect, in high doses - negative foreign and dromotropic, as well as moderate diuretic effect.

    The magnesium ion is a cofactor of 300 enzyme reactions. An indispensable element in the processes ensuring the receipt and expenditure of energy. Participates in the balance of electrolytes, transport of ions, permeability of membranes, neuromuscular excitability. Included in the structure (pentose-phosphate) deoxyribonucleic acid, It participates in the synthesis of ribonucleic acid, the apparatus of heredity, cell growth, in the process of cell division. Limits and prevents excessive release of catecholamine during stress, lipolysis and release of free fatty acids are possible. It is a "physiological" blocker of slow calcium channels. Promotes the penetration of the potassium ion into the cells.

    Aspartate promotes the penetration of the potassium and magnesium ions into the intracellular space, stimulates the intercellular synthesis of phosphates.
    Pharmacokinetics:

    Easily absorbed when ingested and relatively quickly excreted in the urine.

    Indications:

    Aspartame is used in complex therapy for heart failure, coronary heart disease, hypokalemia, heart rhythm disturbances (including myocardial infarction, cardiac glycoside overdose).

    Contraindications:

    Hypersensitivity to the drug, a violation of amino acid metabolism, arterial hypotension, acute and chronic renal failure, hyperkalemia, hypermagnesia, violation of atrioventricular conduction (atrioventricular blockade I-III degree), severe myasthenia gravis, hemolysis, insufficiency of the adrenal cortex, age under 18 years (efficacy and safety not established).

    Carefully:

    Be wary appoint during pregnancy and during breastfeeding lactation.

    Pregnancy and lactation:

    The application is possible if the potential benefit to the mother exceeds the possible risk to the fetus or the baby.

    Dosing and Administration:

    Asparkam is taken orally after eating 1-2 tablets 3 times a day. The course of treatment is 3-4 weeks. If necessary, repeat the course.

    Side effects:

    Possible nausea, vomiting, diarrhea, discomfort or burning in the epigastric region (in patients with an anatomic gastritis or cholecystitis), hyperkalemia (nausea, vomiting, diarrhea, parasthesia), hypermagnia (redness, thirst, lowering blood pressure, hyporeflexia, muscle weakness , paresis, coma, areflexia, respiratory depression, convulsions).

    Overdose:

    Symptoms: conduction disorders (especially with the previous pathology of the conduction system of the heart).

    Treatment: intravenous calcium chloride; if necessary, hemodialysis and peritoneal dialysis.

    Interaction:

    Pharmacodynamic: a joint application with potassium-sparing diuretics (triamterene, spironolactone), beta-adrenoblockers, cyclosporine, heparin, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs increases the risk of developing Hyperkalemia up to the development of arrhythmia and asystole. The use of potassium preparations together with glucocorticosteroids eliminates the hypokalemia caused by the latter. Due to the content of potassium ions, the undesirable effects of cardiac glycosides decrease.

    Due to the content of magnesium ions reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin.

    At simultaneous application the preparation can strengthen the neuromuscular blockade caused by depolarizing muscle relaxants (atrakury bezilatom, decamethonium bromide, suxamethonium (chloride, bromide, iodide)).

    Calcitriol increases the content of magnesium ions in the blood plasma; Calcium preparations reduce the effect of magnesium preparations.

    Pharmacokinetic: astringents and enveloping agents reduce the absorption of the drug in the gastrointestinal tract.

    Special instructions:If heart rhythm disturbances are combined with atrioventricular blockade, Asparcum is not recommended.
    Effect on the ability to drive transp. cf. and fur:There is no information.
    Form release / dosage:Pills.
    Packaging:

    For 8, 10 tablets in a contour mesh box made of a polyvinylchloride film and aluminum foil.

    5, 10 contiguous cell packs of 10 tablets or 7 outline cell packs of 8 tablets with engraved "R" or without engraving "R" with instructions for use are placed in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    Shelf life 3 years.

    Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:LS-002168
    Date of registration:12.05.2011 / 09.06.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:UPDATE OF PFC, CJSC UPDATE OF PFC, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp19.09.2017
    Illustrated instructions
      Instructions
      Up